These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21214668)

  • 1. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream.
    Draelos Z
    Dermatol Surg; 2011 Jan; 37(1):126-7. PubMed ID: 21214668
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream.
    Jeong SY; Shin JB; Yeo UC; Kim WS; Kim IH
    Dermatol Surg; 2010 Jun; 36(6):909-18. PubMed ID: 20384749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of melasma in men with low-fluence Q-switched neodymium-doped yttrium-aluminum-garnet laser versus combined laser and glycolic acid peeling.
    Vachiramon V; Sahawatwong S; Sirithanabadeekul P
    Dermatol Surg; 2015 Apr; 41(4):457-65. PubMed ID: 25760554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of melasma with low fluence, large spot size, 1064-nm Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) laser for the treatment of melasma in Fitzpatrick skin types II-IV.
    Brown AS; Hussain M; Goldberg DJ
    J Cosmet Laser Ther; 2011 Dec; 13(6):280-2. PubMed ID: 21992660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma.
    Goldman MP; Gold MH; Palm MD; Colón LE; Preston N; Johnson LA; Gottschalk RW
    Dermatol Surg; 2011 Feb; 37(2):224-33. PubMed ID: 21269349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of mottled hypopigmentation after low-fluence 1,064-nm Q-switched neodymium-doped yttrium aluminum garnet laser therapy.
    Ryu HJ; Kim J
    J Cosmet Laser Ther; 2013 Oct; 15(5):290-2. PubMed ID: 23464754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of Q-switched 1,064-nm neodymium-doped yttrium aluminum garnet laser treatment of melasma.
    Zhou X; Gold MH; Lu Z; Li Y
    Dermatol Surg; 2011 Jul; 37(7):962-70. PubMed ID: 21615824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma.
    Grimes PE; Bhawan J; Guevara IL; Colón LE; Johnson LA; Gottschalk RW; Pandya AG
    J Am Acad Dermatol; 2010 Jun; 62(6):962-7. PubMed ID: 20398959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Tranexemic Acid With Triple Combination Cream (Flucinolone+Hydroquinone+Tretinoin) Versus Triple Combination Cream Alone In Treatment Of Melasma.
    Basit A; Rahman A; Uddin R
    J Ayub Med Coll Abbottabad; 2021; 33(2):293-298. PubMed ID: 34137548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized controlled trial comparing treatment efficacy and tolerance of picosecond alexandrite laser with a diffractive lens array and triple combination cream in female asian patients with melasma.
    Wang YJ; Lin ET; Chen YT; Chiu PC; Lin BS; Chiang HM; Huang YH; Wang KY; Lin HY; Chang TM; Chang CC
    J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):624-632. PubMed ID: 31494973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melasma treatment with pulsed-dye laser and triple combination cream: a prospective, randomized, single-blind, split-face study.
    Passeron T; Fontas E; Kang HY; Bahadoran P; Lacour JP; Ortonne JP
    Arch Dermatol; 2011 Sep; 147(9):1106-8. PubMed ID: 21931054
    [No Abstract]   [Full Text] [Related]  

  • 12. Q-switched Nd: YAG laser versus trichloroacetic acid peeling in the treatment of melasma among Egyptian patients.
    Moubasher AE; Youssef EM; Abou-Taleb DA
    Dermatol Surg; 2014 Aug; 40(8):874-82. PubMed ID: 25068546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Punctate leucoderma after 1,064-nm Q-switched neodymium-doped yttrium aluminum garnet laser with low-fluence therapy: is it melanocytopenic or melanopenic?
    Kim T; Cho SB; Oh SH
    Dermatol Surg; 2010 Nov; 36(11):1790-1. PubMed ID: 20961356
    [No Abstract]   [Full Text] [Related]  

  • 14. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads.
    Torok H; Taylor S; Baumann L; Jones T; Wieder J; Lowe N; Jarret M; Rich P; Pariser D; Tschen E; Martin D; Menter A; Weiss J
    J Drugs Dermatol; 2005; 4(5):592-7. PubMed ID: 16167418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma.
    Cestari T; Adjadj L; Hux M; Shimizu MR; Rives VP
    J Drugs Dermatol; 2007 Feb; 6(2):153-60. PubMed ID: 17373174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma.
    Grimes PE
    Cutis; 2007 Dec; 80(6):497-502. PubMed ID: 18246882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream.
    Bhawan J; Grimes P; Pandya AG; Keady M; Byers HR; Guevara IL; Colón LE; Johnson LA; Gottschalk R
    Am J Dermatopathol; 2009 Dec; 31(8):794-8. PubMed ID: 19755910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Objective assessment of erythema and pigmentation of melasma lesions and surrounding areas in long-term management regimens with triple combination.
    Hexsel D; Soirefmann M; Fernandes JD; Siega C
    J Drugs Dermatol; 2014 Apr; 13(4):444-8. PubMed ID: 24719064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma.
    Monheit GD; Dreher F
    J Drugs Dermatol; 2013 Mar; 12(3):270-4. PubMed ID: 23545908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
    Chan R; Park KC; Lee MH; Lee ES; Chang SE; Leow YH; Tay YK; Legarda-Montinola F; Tsai RY; Tsai TH; Shek S; Kerrouche N; Thomas G; Verallo-Rowell V
    Br J Dermatol; 2008 Sep; 159(3):697-703. PubMed ID: 18616780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.